Orion Porfolio Solutions LLC Has $37.15 Million Stock Position in AbbVie Inc. $ABBV

Orion Porfolio Solutions LLC lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 160,438 shares of the company’s stock after selling 2,413 shares during the period. Orion Porfolio Solutions LLC’s holdings in AbbVie were worth $37,148,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Evolution Wealth Management Inc. acquired a new position in AbbVie during the 2nd quarter worth about $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie in the second quarter valued at approximately $28,000. Caitlin John LLC acquired a new stake in AbbVie during the 3rd quarter valued at approximately $33,000. Financial Gravity Companies Inc. bought a new position in AbbVie during the 2nd quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC bought a new position in AbbVie during the 2nd quarter worth approximately $39,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.9%

Shares of NYSE ABBV opened at $235.90 on Thursday. The firm has a market capitalization of $417.11 billion, a P/E ratio of 99.96, a P/E/G ratio of 0.81 and a beta of 0.34. The firm’s 50-day moving average price is $224.68 and its 200-day moving average price is $223.75. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the company posted $2.16 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.25% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on ABBV. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Evercore decreased their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Finally, Berenberg Bank set a $275.00 target price on AbbVie in a research note on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab in moderately‑to‑severely active Crohn’s disease — higher clinical remission and endoscopic response vs. placebo, boosting the potential of another high‑value immunology franchise for AbbVie and supporting upside to long‑term revenue. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: Advances venetoclax into a Phase 2 program for rare blood cancers (Japan) — extends oncology pipeline and creates additional potential mid‑term revenue streams if signals hold. Pipeline expansion helps justify premium multiples. AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) highlights Medical Weight Loss data showing shifting patient demand — supports growth in aesthetics segment and recurring/procedural revenue opportunities. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
• Positive Sentiment: Capacity/expansion news that boosts supply resilience for immunology medicines — lowers execution risk for core products (Skyrizi, Rinvoq) and supports steady cash flows. AbbVie (NYSE:ABBV) Expansion Boosts Supply Resilience For Immunology Medicines S&P 500
• Positive Sentiment: Analyst / editorial interest and cash‑flow narratives highlight AbbVie as a strong free‑cash‑flow generator with an attractive dividend profile — supports investor appetite for yield + growth. These 3 Cash Flow Machines Provide Stability in Uncertain Markets
• Neutral Sentiment: Large senior notes offering completed (~$7.5–8.0B) — provides financing flexibility (refinancing, M&A, capex) but increases gross leverage and interest cash outflows; market reaction depends on use of proceeds and refinancing terms. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Neutral Sentiment: Corporate presentations and conference appearances (TD Cowen, Leerink) scheduled — management visibility may provide more near‑term guidance or pipeline color but are information events rather than direct catalysts. AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Negative Sentiment: AbbVie lost an effort to block Tennessee’s 340B law — potential downside for pricing/reimbursement in a pharmacy‑discount program context; could pressure margins or access in affected channels if replicated elsewhere. AbbVie loses bid to block Tennessee 340B law
• Neutral Sentiment: Technical/market commentary notes ABBV stabilizing near resistance around $233 — useful for short‑term traders but secondary to the fundamental news above. AbbVie: Stabilizes Near $233 While Testing Resistance

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.